Advanced search
Publication Cover
Upsala Journal of Medical Sciences Volume 122, 2017 - Issue 2
Journal homepage
3,205
Views
17
CrossRef citations to date
0
Altmetric
Review Article

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside

Sten-Magnus AquiloniusDepartment of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden
&
Dag NyholmDepartment of Neuroscience, Neurology, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
Pages 71-77 | Received 01 Dec 2016, Accepted 17 Jan 2017, Published online: 03 Mar 2017

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Nbaa Masood & Joohi Jimenez-Shahed. (2023) Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs. Neuropsychiatric Disease and Treatment 19, pages 247-266.
Read now
Thomas Müller. (2020) An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease. Expert Opinion on Pharmacotherapy 21:14, pages 1659-1665.
Read now
Thomas Müller. (2020) Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 403-414.
Read now
Thomas Müller & Jan-Dominique Möhr. (2018) Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease. Expert Opinion on Pharmacotherapy 19:18, pages 2063-2071.
Read now
Thomas Müller & Jan-Dominique Möhr. (2018) Long-term management of Parkinson’s disease using levodopa combinations. Expert Opinion on Pharmacotherapy 19:9, pages 1003-1011.
Read now

Articles from other publishers (12)

Ankita Wal, Pranay Wal, Himangi Vig, Nem Kumar Jain, Shruti Rathore, Karthickeyan Krishnan & Ashish Srivastava. (2023) Treatment of Parkinson's Disease: Current Treatments and Recent Therapeutic Developments. Current Drug Discovery Technologies 20:5.
Crossref
Dag Nyholm & Wolfgang H. Jost. (2022) Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance. Therapeutic Advances in Neurological Disorders 15, pages 175628642211080.
Crossref
Thomas Müller. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 2853 2870 .
Helga María Grétarsdóttir, Erik Widman, Anders Johansson & Dag Nyholm. (2021) Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice. Journal of Personalized Medicine 11:8, pages 720.
Crossref
Mohammad Al Majali, Michael Sunnaa & Pratap Chand. (2021) Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease. Journal of Geriatric Psychiatry and Neurology 34:4, pages 263-273.
Crossref
Florence Véronneau-Veilleux, Philippe Robaey, Mauro Ursino & Fahima Nekka. (2020) An integrative model of Parkinson’s disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression. Journal of Pharmacokinetics and Pharmacodynamics 48:1, pages 133-148.
Crossref
Daniele Urso, K. Ray Chaudhuri, Mubasher A. Qamar & Peter Jenner. (2020) Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies. CNS Drugs 34:11, pages 1149-1163.
Crossref
Govindarajan Karthivashan, Palanivel Ganesan, Shin-Young Park, Ho-Won Lee & Dong-Kug Choi. (2020) Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies. Biomaterials 232, pages 119704.
Crossref
Grażyna Söderbom & Bai-Yun Zeng. 2020. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Neurodegenerative Disease Research and Commonalities with Metabolic Diseases. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Neurodegenerative Disease Research and Commonalities with Metabolic Diseases 345 391 .
Grażyna Söderbom. 2020. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Neurodegenerative Disease Research and Commonalities with Metabolic Diseases. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Neurodegenerative Disease Research and Commonalities with Metabolic Diseases 153 188 .
Thomas Müller. 2019. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 18 .
Harsh V. Gupta, Kelly E. Lyons & Rajesh Pahwa. (2019) Old Drugs, New Delivery Systems in Parkinson’s Disease. Drugs & Aging 36:9, pages 807-821.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.